Business Description
![TG Therapeutics Inc TG Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000087N.png?14)
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
TGTX: Ordinary SharesDescription
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.88 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | 2.07 | |||||
Interest Coverage | 4.01 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.62 | |||||
Beneish M-Score | 26.44 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1063 | |||||
3-Year FCF Growth Rate | 51.5 | |||||
3-Year Book Growth Rate | -34 | |||||
Future 3-5Y Total Revenue Growth Rate | 44.06 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 85.92 | |||||
9-Day RSI | 81.18 | |||||
14-Day RSI | 76.1 | |||||
6-1 Month Momentum % | 4.95 | |||||
12-1 Month Momentum % | -25.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.62 | |||||
Quick Ratio | 2.84 | |||||
Cash Ratio | 2.1 | |||||
Days Inventory | 813.47 | |||||
Days Sales Outstanding | 45.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | -0.67 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.53 | |||||
Operating Margin % | 16.71 | |||||
Net Margin % | 14.24 | |||||
FCF Margin % | 7.01 | |||||
ROE % | 37.23 | |||||
ROA % | 14.18 | |||||
ROIC % | 94.75 | |||||
ROC (Joel Greenblatt) % | 145.95 | |||||
ROCE % | 24.28 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 99.84 | |||||
Forward PE Ratio | 91.39 | |||||
PE Ratio without NRI | 99.84 | |||||
PS Ratio | 11.59 | |||||
PB Ratio | 21.12 | |||||
Price-to-Tangible-Book | 21.33 | |||||
Price-to-Free-Cash-Flow | 221.85 | |||||
Price-to-Operating-Cash-Flow | 221.85 | |||||
EV-to-EBIT | 59.31 | |||||
EV-to-EBITDA | 58.89 | |||||
EV-to-Revenue | 11 | |||||
EV-to-Forward-Revenue | 10.77 | |||||
EV-to-FCF | 157.23 | |||||
Price-to-Graham-Number | 9.73 | |||||
Price-to-Net-Current-Asset-Value | 23.16 | |||||
Earnings Yield (Greenblatt) % | 1.69 | |||||
FCF Yield % | 0.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 289.334 | ||
EPS (TTM) ($) | 0.22 | ||
Beta | 2.28 | ||
Volatility % | 101.03 | ||
14-Day RSI | 76.1 | ||
14-Day ATR ($) | 0.877682 | ||
20-Day SMA ($) | 18.805 | ||
12-1 Month Momentum % | -25.11 | ||
52-Week Range ($) | 6.46 - 22.67 | ||
Shares Outstanding (Mil) | 154.54 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TG Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(TGTX)'s stock price today?
The current price of TGTX is $21.97. The 52 week high of TGTX is $22.67 and 52 week low is $6.46.
When is next earnings date of TG Therapeutics Inc(TGTX)?
The next earnings date of TG Therapeutics Inc(TGTX) is 2024-08-01 Est..
Does TG Therapeutics Inc(TGTX) pay dividends? If so, how much?
TG Therapeutics Inc(TGTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |